Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May 29 2007.

Slides:



Advertisements
Similar presentations
Design of high-content and focused libraries to improve the development of new active compounds in the framework of the rational drug discovery Design.
Advertisements

FRAGMENT- BASED DRUG DESIGN Yemane Mengistu Michigan State University January 30, 2008.
Analysis of High-Throughput Screening Data C371 Fall 2004.
3D Molecular Structures C371 Fall Morgan Algorithm (Leach & Gillet, p. 8)
In silico small molecule discovery Sales Target gene Discover hit Hit to lead Optimise lead Clinical Target gene identified with a viable assay High throughput.
Chemical Biology 1 – Pharmacology Methods for studying protein function – Loss of Function 1. Gene knockouts 2. Conditional knockouts 3. RNAi.
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
Lipinski’s rule of five
FBDD Advantages? Disadvantages? What is a fragment?
Novel Dihydrofolate Reductase Inhibitors. Structure- Based versus Diversity-Based Design and High- Throughput Synthesis and Screening Pierre C. Wyss, Paul.
Biol518 Lecture 2 HTS and Antibiotic Drug Discovery.
BACE-1 Inhibitors Alzheimer’s Disease Application of Fragment-Based NMR Screening, X-ray Crystallography, Structure-Based Design, and Focused Chemical.
Organic Chemistry 4 th Edition Paula Yurkanis Bruice Irene Lee Case Western Reserve University Cleveland, OH ©2004, Prentice Hall Chapter 30 The Organic.
1111 Discovery Novel Allosteric Fragment Inhibitors of HIV-1 Reverse Transcriptase for HIV Prevention A/Prof Gilda Tachedjian Retroviral Biology and Antivirals.
In Silico Design of Selective Estrogen Receptor Modulators from Triazoles and Imines Joey Salisbury Dr. John C. Williams Small Molecules/Large Molecules.
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
LSM2104/CZ2251 Essential Bioinformatics and Biocomputing Essential Bioinformatics and Biocomputing Protein Structure and Visualization (3) Chen Yu Zong.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Structure-based Drug Design
Chapter 9: Making new antibiotics. Model organisms are used to speed drug discovery A model organism is a non-human species that is extensively studied.
Computational Techniques in Support of Drug Discovery October 2, 2002 Jeffrey Wolbach, Ph. D.
Functional groups / Pharmacological Activity
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
Chapter 3 Nucleic Acids, Proteins and Enzymes. Nucleic Acids Informational polymers Made of C,H,O,N and P No general formula Examples: DNA and RNA.
Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 02 – MECHANISMS OVERVIEW.
Topological Summaries: Using Graphs for Chemical Searching and Mining Graphs are a flexible & unifying model Scalable similarity searches through novel.
VAMOS Visualization of Accessible Molecular Space A new compound filtering and selection interface Spotfire User Conference - Europe - May , 2003.
A genetic algorithm for structure based de-novo design Scott C.-H. Pegg, Jose J. Haresco & Irwin D. Kuntz February 21, 2006.
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
Genome organization. Nucleic acids DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) store and transfer genetic information in living organisms.
Topics covered Scope and applications of insilico modeling in modern biology. Comparative modeling Constructing an initial model refining the model manipulating.
DE NOVO DESIGN OF A THYMIDYLATE KINASE INHIBITOR.
Faculté de Chimie, ULP, Strasbourg, FRANCE
Biology 2.3 Carbon Compounds
PHC 222 Medicinal Chemistry-1- Part(I) Dr. Huda Al Salem Lecture (1)
CHAPTER 2 CHEMISTRY OF LIFE. 2-1 The Nature of Matter.
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
Ligand-based drug discovery No a priori knowledge of the receptor What information can we get from a few active compounds.
Noncovalent Molecular Forces - Part 1 Lecture Supplement page 200 F-F-        
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
What our bodies are made of Chemistry of Cells. Nature of Matter All matter is made of atoms. Atoms consist of electrons, protons and neutrons. Molecules.
Bioinformatics MEDC601 Lecture by Brad Windle Ph# Office: Massey Cancer Center, Goodwin Labs Room 319 Web site for lecture:
Biology Chapter 8 Section 3. Key Ideas  How do cells use signal molecules?  How do cells receive signals?  How do cells respond to signaling?
End Show Slide 1 of 37 Copyright Pearson Prentice Hall Biology.
Catalyst TM What is Catalyst TM ? Structural databases Designing structural databases Generating conformational models Building multi-conformer databases.
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
김소연 Permeability OverviewPermeability FundamentalsPermeability EffectPermeability Structure Modification StrategiesProblem.
Marlou Snelleman 2012 Protein structure. Overview Sequence to structure Hydrogen bonds Helices Sheets Turns Hydrophobicity Helices Sheets Structure and.
Essential Questions How does the structure of water make it a good solvent? What are the similarities and differences between solutions and suspensions?
Elon Yariv Graduate student in Prof. Nir Ben-Tal’s lab Department of Biochemistry and Molecular Biology, Tel Aviv University.
The Chemistry of Carbon Organic compounds - compounds created by organisms Organic compounds - compounds created by organisms 4 groups of organic compounds.
Molecular Modeling in Drug Discovery: an Overview
Natural products from plants
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Lipinski’s rule of five
CHM 708: MEDICINAL CHEMISTRY
Proteins Dr. Ron Rusay Spring 2004 © Copyright 2004 R.J. Rusay.
Organic Compounds.
Computational design of protein function
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
DATA MINING FOR SMALL MOLECULE ALLOSTERIC INHIBITORS
Molecular Docking Profacgen. The interactions between proteins and other molecules play important roles in various biological processes, including gene.
Virtual Screening.
Rules for Rapid Property Profiling from Structure
“Structure Based Drug Design for Antidiabetics”
Structure-based drug design: progress, results and challenges
FUNDAMENTALS OF CHEMISTRY
Amino Acids An amino acid is any compound that contains an amino group (—NH2) and a carboxyl group (—COOH) in the same molecule.
Structure-Guided Design of Fluorescent S-Adenosylmethionine Analogs for a High- Throughput Screen to Target SAM-I Riboswitch RNAs  Scott F. Hickey, Ming C.
Cheminformatics Basics
Presentation transcript:

Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May

Small Molecule and Large Molecule Drug Design “Small Molecule” Drugs –Low MW –Moderately hydrophobic/hydrophilic –Moderately chemical complexity “Biologicals” –Peptides/peptidomimetics –Engineered enzymes –Antisense/RNAi –Need help to enter cells!

“New Tools” for Drug Discovery (1980s and 90s) Combinatorial Chemistry Increased the number of available compounds High Throughput Screening (“HTS”) Increases throughput for testing (robotics, databasing) “It’s a Numbers Game”

Rational Drug Design = the Opposite of “It’s a Numbers Game” Protein Structure Design small molecule to “fit” and block active site Voila! Doesn’t work! In Silico High Throughput Docking: A rational numbers game

Membrane Permeability & “Drug- Likeness” The Lipinski “Rule of Five”

Fragment Library Design Fragments must be “lead-like” not “drug- like” MW < 250, allows compound to “grow” Weak binding affinity (will add affinity with growth) Contain polar groups –Insures solubility –Polar groups are reactive –Pick up hydrogen bonding interactions N fragments can cover the chemical space of N 2 compounds

Lipinski Rule of 5 Molecular Weight < 500 Daltons cLogP < 5 < 10 Acceptor Groups (O+N) < 5 Donor Groups ( O-H, N-H) Exceptions work by active transport Paromomycin MW 616 Erythromycin MW 734 Tetracycline MW 444 Thiostrepton MW 1665

Examples of Small Molecule Molders/Regulators of RNA Secondary Structure in Bacteria 2,6 diaminopurine K d =10 nM Purine K d =100 µM SAH No effect SAM K d = nM

Examples of Small Molecule Molders/Regulators of RNA Secondary Structure in Bacteria L-Lysine K d =1 µM D-Lysine No effect FMN Kd=5 nM Riboflavin Kd=3 µM

druggable RNA- binding Protein- binding a b c Lipinski

Current Databases Pdb title search: RNA gets 2173 hits: “ternary” Structure description search for ribonucleic acid: 6 hits (2 DNA) NDB search for RNA + ligand: 841 hits, including protein/RNA complex Most ligand databases oriented to search for proteins/ligands

Database of RNA Binding Compounds Antibiotics Antibiotics Riboswitch ligands Riboswitch ligands Drug discovery programs (published) Drug discovery programs (published) Published findings of natural products Published findings of natural products 105 compounds in all 105 compounds in all

Database of RNA Binding Compounds (caveats) Only 25 compounds had pdb coordinates Only 25 compounds had pdb coordinates Reported K d < 50 μM Reported K d < 50 μM Redundancy: does not include near neighbors Redundancy: does not include near neighbors pdb coordinates did not identify non- contacting substructures pdb coordinates did not identify non- contacting substructures

Database of RNA Binding Compounds (further needs) DNA binding compounds DNA binding compounds Classification Classification Correlation with RNA motifs/pharmacophores Correlation with RNA motifs/pharmacophores

Fragment based approaches >500k compounds screened assays usually require  M hits Template decoration often prevents interaction Need to reduce MW of weak binders prior to modification HTS Paradigm X HTS requires “right” compounds in library SeeDs Paradigm Drug lead-like fragments No steric inhibition of scaffolds ~ mM binding (Structural Exploration of Exploitable Drug Startpoints) X-ray/NMR Chemistry SBDD Grow potent, selective ligands from fragment